Program
denecimig
Also written as “NNC0365-3769 (Mim8)”, “Mim8” and “Denecimig”.
Its studies are mostly in Hemophilia A, led by Novo Nordisk.
Furthest: phase 3, since Sep 13, 20217 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 72 open or running | phase 3since Sep 13, 2021 | Dec 17, 2019 | Jun 30, 2028phase 3 · NCT05685238 |
- Named in Novo Nordisk’s own pipeline as
Denecimig (Mim8) in haemophilia A
, phase 4, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2019First study: phase 2 study in Healthy VolunteersFirst studyNCT04204408 · 275 enrolled · United States, Austria, Bulgaria and more
- Sep 13, 2021Phase 3 study in Hemophilia ANCT05053139 · 281 enrolled · United States, Austria, Belgium and more
- Mar 23, 2022Phase 3 study in Haemophilia A With or Without InhibitorsNCT05306418 · 70 enrolled · United States, Canada, China and more
- Jan 4, 2023Phase 3 study in Hemophilia ANCT05685238 · 451 enrolled · United States, Austria, Belgium and more
- Jan 4, 2023Phase 1 study in Hemophilia ANCT05681845 · 205 enrolled · Germany
- May 12, 2023Phase 3 study in Hemophilia ANCT05878938 · 61 enrolled · United States, Austria, Belgium and more
- Sep 15, 2026Phase 3 study in Hemophilia ANCT07830732 · 84 planned · United States, Argentina, Australia and more
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Hemophilia ANCT05685238
- Mar 23, 2029Primary completion: phase 3 study in Hemophilia ANCT07830732
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07830732Hemophilia A · United States, Argentina, Australia and more | 3 | Recruiting | Mar 23, 2029 | 84 |
| NCT05878938Hemophilia A · United States, Austria, Belgium and more | 3 | Completed | Jul 18, 2024 | 61 |
| NCT05685238Hemophilia A · United States, Austria, Belgium and more | 3 | Active, not recruiting | Jun 30, 2028 | 451 |
| NCT05681845Hemophilia A · Germany | 1 | Completed | Oct 13, 2023 | 205 |
| NCT05306418Haemophilia A With or Without Inhibitors · United States, Canada, China and more | 3 | Completed | Nov 13, 2024 | 70 |
| NCT05053139Hemophilia A · United States, Austria, Belgium and more | 3 | Completed | Mar 11, 2024 | 281 |
| NCT04204408Healthy Volunteers · United States, Austria, Bulgaria and more | 2 | Completed | Oct 6, 2023 | 275 |
How it is read
Names in the registry
- “NNC0365-3769 (Mim8)”, 3 entries
- “Mim8”, 2 entries
- “Denecimig”, 1 entry
- “NNC0365-3769 (Mim8) PPX”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.